Top Markets
#1 Black Phoenix Black Phoenix +333.52%
#2 Islamic Coin Islamic Coin +158.18%
#3 Glidr Glidr +58.56%
#4 Cryptopia Cryptopia +21.05%
#5 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.65%
#6 DOVU DOVU +15.63%
#7 Palladium Network Palladium Network +8.75%
#8 Pons Pons +7.99%
#9 stake.link stake.link +7.92%
#10 Movement Movement +6.59%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
Response Genetics, Inc Response Genetics, Inc

Response Genetics, Inc

RGDXQ
Rank in Stocks #42156
Response Genetics, Inc., a life sciences company founded in Los Angeles,... Response Genetics, Inc., a life sciences company founded in Los Angeles, California, in 1999 (originally Bio Type, Inc., before its rebranding in August 2000), focuses on creating, advancing, and commercializing pharmacogenomic tests. These diagnostic tools are crucial for informing cancer treatment decisions by assessing specific indicators within tumor tissue samples that predict a patient's response to therapy. The company provides an extensive array of testing services, primarily through its ResponseDX suite, covering various cancers such as non-small cell lung, colorectal, gastric, gastroesophageal, melanoma, thyroid, breast, and glioma, in addition to a Tissue of Origin test. Beyond these existing solutions, Response Genetics is committed to expanding its diagnostic offerings to encompass other tumor types, while also delivering both the technical execution and professional interpretation components of its testing services. Operating globally, with a significant presence in the United States and Europe, Response Genetics serves a wide range of clients including community oncologists, pathologists, medical practices, hospitals, and pharmaceutical enterprises, primarily through its internal sales force.
Share Price
$0.0001
Last synced: 2026-08-11
Market Cap
$3.87K
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Response Genetics, Inc (RGDXQ)

Category

Healthcare
P/E ratio for Response Genetics, Inc (RGDXQ)
P/E ratio as of 2026 TTM: 0
According to Response Genetics, Inc latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Response Genetics, Inc from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Thermo Fisher Scientific Inc. Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc.
TMO.US
 30.84 -
US
Danaher Corporation Danaher Corporation
Danaher Corporation
DHR.US
 34.53 -
US
WuXi AppTec Co., Ltd. WuXi AppTec Co., Ltd.
WuXi AppTec Co., Ltd.
603259.SS
 - -
CN
IDEXX Laboratories, Inc. IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc.
IDXX.US
 40.90 -
US
Natera, Inc. Natera, Inc.
Natera, Inc.
NTRA.US
 -164.27 -
US
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.